Alloplex Biotherapeutics announces the attendance of its Scientific Founder and CEO, Dr. Frank Borriello, at the BIO International Convention, taking place in Boston from June 16-19, 2025. This prominent event brings together leaders from across the biotechnology ecosystem.
Dr. Borriello will be available to meet with potential strategic partners in cell therapy to discuss Alloplex’s non-engineered immune cell training approach to cancer immunotherapy. Discussions will focus on the ENLIST immune cell training platform and its lead program, SUPLEXA.
SUPLEXA has demonstrated exceptional safety and inherent single agent antitumor activity in Phase 1 clinical trials. The technology represents a wholly-differentiated, multi-modal (non-engineered) autologous approach to retrain a patient’s own immune cells. The ENLIST platform also offers versatility to augment existing cell therapy modalities.
Companies with an existing commitment to cell therapy interested in exploring potential collaborations can schedule a meeting with Dr. Borriello through the BIO Partnering™ platform or by contacting office@alloplexbio.com.